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Introduction
Sumatriptan is a selective agonist at vascular 5-hydrox-
ytriptamine 1B/1D receptor subtypes with high affinity
and relative specificity for the 5-HT1D receptor subtype.
Sumatriptan is rapidly absorbed after oral administration,
with 80% of the maximum plasma concentration (Cmax)
occurring 45 min after administration of a single 100 mg
dose, and a median Cmax of 49 ng/ml. Time to Cmax ranges
from 0.5 to 3–4 h [1].
Sumatriptan is very rapidly absorbed into the systemic
circulation following subcutaneous dosing; in fasting sub-
jects peak plasma concentration occurs within 20 min. The
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Abstract Sumatriptan is a selective
agonist of 5HT1 (1B/1D) receptors,
which has proved to be effective
and safe for the acute treatment of
migraine attacks. Nevertheless, its
use by migraine sufferers is still
limited and some patients consider
adverse reactions related to suma-
triptan, especially chest symptoms,
unacceptable even if not serious.
Moreover, in clinical trials, almost
one third and one sixth of patients,
respectively, fail to experience
headache relief either after oral or
after subcutaneous sumatriptan
administration. Our aim was to ver-
ify whether differencies in suma-
triptan pharmacokinetics could
explain non-response and/or
adverse drug reactions. Sumatriptan
levels were determined by HPLC
with electrochemical detection.
Pharmacokinetic parameters were
calculated using a computer pro-
gram (PK Solutions 2.0; non com-
partmental Pharmacokinetics Data
Analysis). After oral administration,
sumatriptan is rapidly absorbed and
sometimes displays multiple peaks
of plasma concentration. This “mul-
tiple peaking” gives rise to consid-
erable inter-subject variability in
the time of reaching maximum
plasma concentration.
Pharmacokinetic parameters of
sumatriptan, both after oral and
subcutaneous administration, were
similar in the three patient groups.
Blood pressure and heart rate did
not show any significant differences
between groups. Pharmacokinetic
parameters and bioavailability of
sumatriptan did not seem to be cor-
related either to the lack of efficacy
or the appearance of side effects.
These results could depend on the
limited number of patients studied.
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extent of absorption of sumatriptan by the subcutaneous
route is 96%–97%, whereas it is much lower by the oral
route. This lower bioavailability following oral administra-
tion is mainly the result of pre-systemic metabolism in the
gut wall and in the liver, and consequently the inter-subject
variability in plasma concentrations is much greater follow-
ing oral dosing than after parenteral administration [2].
Sumatriptan has proved to be effective and safe for the
acute treatment of migraine attacks [3]. Nevertheless, its
use by migraine sufferers is still limited, and some
patients consider adverse reactions related to sumatriptan,
especially chest symptoms, unacceptable, even if not seri-
ous [4]. Moreover, in clinical trials, almost one third and
one sixth of patients, respectively, fail to experience
headache relief either after oral or after subcutaneous
sumatriptan administration. The mechanism of headache
relief could be correlated to the rate of initial rise of plas-
ma levels (Tmax), to the height of the plasma levels
reached (Cmax) and to the oral bioavailability [5].
Two different hypotheses have been put forward to
explain the variability of sumatriptan therapeutic effec-
tiveness: the first, of a pharmacodynamic nature, is con-
nected to receptorial responsivity; the second one, of a
pharmacokinetic nature, concerns sumatriptan absorption,
distribution, elimination and bioavailability.
We investigated whether differences exist in the phar-
macokinetic profiles of sumatriptan and in its relative oral
bioavailability among patients with different clinical
responses to this drug.
Methods
So far, we determined sumatriptan pharmacokinetics in the fol-
lowing migraine patients: group 1, 3 females (mean age±SD:
51.5±12.0 years), who obtained headache relief; group 2, 3
males (mean age±SD: 49.0±1.4 years), who were non-respon-
ders; group 3, 3 females (mean age±SD: 37.0±1.2 years) who
reported unacceptable adverse drug reactions. Each subject was
studied twice, after oral and after subcutaneous administration of
sumatriptan. A 1-week washout period was allowed between the
administration of the two formulations. Patients were studied
outside migraine attacks.
Blood samples were taken at baseline, at 15 and 30 min and
at 1, 2, 3, 4, 5 and 6 h after sumatriptan oral administration, and
at baseline and at 2, 5, 10, 15, 20, 25, 30, 60, 90, 120, and180
min after subcutaneous injection. Vital signs and adverse reac-
tions were checked at each blood sampling. Sumatriptan levels
were determined by HPLC with electrochemical detection.
Pharmacokinetic parameters were calculated using a computer
programme (PK Solutions 2.0; Non-Compartmental
Pharmacokinetics Data Analysis).
The following parameters were evaluated: elimination half-
life (Ehalf-life), absorption half-life (Ahalf-life), peak plasma con-
centration (Cmax), time to peak plasma concentration (Tmax), area
under the plasma concentration computed using observed data
points only (AUC0–t), area under the plasma concentration com-
puted using data points extrapolated to infinity (AUC0–inf), mean
residence time, time for 63.2% of administered dose to be elim-
inated (MRT), apparent volume of distribution (Vd) and sys-
temic clearance (Cl). The relative values of AUC after oral
sumatriptan administration and AUC after subcutaneous admin-
istration, referred to unit dose, provide the relative oral bioavail-
ability of the drug.
Results
The pharmacokinetic parameters obtained following subcu-
taneous administration of sumatriptan (6 mg) (Table 1) were
found to be within the ranges reported in previous studies
[6], and to confirm at the same time the minimal inter-indi-
vidual variability of plasma concentrations of the drug in all
three patient groups. The statistical analysis failed to show
Table 1 Pharmacokinetic parameters (mean±SD) of sumatriptan in migraine patients following 6 mg subcutaneous administration
Ehalf-life, Ahalf-life, Cmax, tmax, AUC0–t, AUC0–∞, MRT, Vd, Cl, 
min h ng/ml min ng/min/ml ng/min/ml min ml/kg ml/min/kg
1st group 70.0±16.0 1.5±0.5 79.5±37.9 7.5±3.5 3106.8±1546.3 3575.5±1381.8 69.0±13.4 3045.5±466.8 31.5±11.8
2nd group 73.1±8.6 2.7±1.5 50.5±17.6 15.0±7.1 4648.9±2911.2 5158.0±2628.9 105.0±9.8 1923.1±1200.5 17.7±9.2
3rd group 66.5±18.9 2.9±2.5 55.6±5.3 12.5±3.5 3924.2±544.3 4121.7±476.9 76.5±15.9 2339.8±346.3 24.9±3.5
Table 2 Pharmacokinetic parameters (mean±SD) of sumatriptan in migraine patients following 100 mg oral administration
Ehalf-life, Ahalf-life, Cmax, tmax, AUC0–t, AUC0–∞, MRT, Vd, Cl, 
min h ng/ml min ng/min/ml ng/min/ml min ml/kg ml/min/kg
lst group 90.9±39.5 39.9±5.5 44.7±4.4 110.0±17.3 9357.1±2393.9 11910.6±5208.6 219.3±39.9 14341.3±6640.7 132.9±108.4
2nd group 84.4±11.8 41.1±9.1 48.4±1.6 165.0±106.1 11908.2±108.7 14672.6±1688.4 247.6±51.0 10914.9±470.1 90.2±8.7
3rd group 67.0±11.2 43.4±31.0 58.9±6.1 180.0±127.3 9606.0±371.2 11301.2±1935.6 222.6±81.3 7261.4±208.4 76.3±14.9
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any significant difference for all kinetic parameters follow-
ing subcutaneous administration. Our results agree with
those obtained in non-respondent subjects [7].
Also, the pharmacokinetic parameters obtained follow-
ing oral administration of sumatriptan 100 mg (Table 2)
conform to those reported in the literature [6]. No evidence
of significant differences between patients was found.
Comparison between relative oral bioavailability of suma-
triptan for the three patient groups showed a tendential, but
non-significant decrease in the amount of the available
drug. The differences of average increase of arterial pres-
sure values between respondent and non-respondent
patients were not significant. Heart rate remained quite sta-
ble (practically unchanged) in all patients.
Conclusions
Our study shows that pharmacokinetic parameters and
bioavailability of sumatriptan did not seem to be correlat-
ed either to the lack of efficacy or the appearance of side
effects. These results could depend on the limited number
of patients studied up to now.
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